|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The role of the AP-1 transcription factors c-Fos,FosB,Fra-1 and Fra-2 in the invasion process of mammary carcinomas显示文摘 | Milde-Langosch K Roder H Andritzky B | 2004 | Breast Cancer Res Treat2004，86，2： | 1 |
| 2 | Elevated pretreatment se- rum concentration of YKL-40-An independent prognostic bio- marker for poor survival in patients with metastatic nonsmall cell lung cancer 显示文摘 | Thorn I Andritzky B Schuch G | 2010 | Cancer2010，116，17： | 1 |
| 3 | The role of the AP-1 transcription factors c-Fos,FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas显示文摘 | Milde-Langosch K Roder H Andritzky B | 2004 | Breast Cancer Res Treat2004，86，2： | 1 |
| 4 | Macroeconomic fundamentals,price discovery,and volatility dynamics in emerging bond markets显示文摘 | Sylwia Nowak Jochen Andritzky Andreas Jobst Natalia Tamirisa | | 0，，： | 1 |
| 5 | The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 ariel Fra-2 in the invasion process of mammary carcinomas显示文摘 | Milde-Langosch K Roder H Andritzky B | 2004 | Breast Cancer Res Treat2004，86，2： | 1 |
| 6 | Elevated pretreatment serum concentration of YKL - 40, An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer 显示文摘 | Thorn I Andritzky B Sehuch G | 2010 | Cancer2010，116，17： | 1 |
| 7 | Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years显示文摘 | Thom I Rogers C Andritzky B | 2009 | Onkologie2009，32，12： | 1 |
| 8 | Single-center management of136 patients with cancer of unknown primary site ( CUP syndrome) o-ver a period of 10 years显示文摘 | Thom I Rogers C Andritzky B | 2009 | Onkologie2009，32，12： | 1 |
| 9 | Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)显示文摘 | Eckart Laack Antje Scheffler Iris Burkholder Ina Boeters Birte Andritzky Gunter Schuch Michael G?rn Gaby Vohwinkel Lutz Edler Walter Fiedler Dieter Kurt Hossfeld | 2005 | Lung Cancer2005，，1： | 1 |
| 10 | Docetaxel and cisplatin as first - line treatment for patients with metastatic esophageal cancer: a pilot study 显示文摘 | Laack E Andritzky B Durk H | 2005 | Onkologie2005，28，12： | 1 |
| 11 | The role of theAP-1 transcription factors c-Fos,FosB,Fra-1 and Fra-2 in theinvasion process of mammary carcinomas显示文摘 | Milde-Langosch K Roder H Andritzky B | 2004 | Breast Cancer Res Treat2004，86，2： | 1 |
| 12 | Elevated pretreat- ment serum concentration of YKI-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer显示文摘 | Thom I Andritzky B Schuch G | 2010 | Cancer2010，116，7： | 1 |
| 13 | Single-center management of 136 patients with cancer of unknown primary site( CUP syndrome) o- ver a period of 10 years显示文摘 | Th6m I Rogers C Andritzky B | 2009 | Oncologie2009，32，12： | 1 |
| 14 | Elevated prctmatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nnnsmall cell lung cancer 显示文摘 | Thom I Andritzky B Schuch G | 2010 | Cancer2010，116，17： | 1 |
| 15 | Elevated pretreatment ser- um concentration of YKL40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer显示文摘 | ThSm I Andritzky B Schuch G | 2010 | Cancer2010，116，17： | 1 |
| 16 | Docetaxel and cisptatin as first line treatment for patients with metastatic esophageal cancer: a pilot study显示文摘 | Laack E Andritzky B Durk H | 2005 | Onkologie2005，28，12： | 1 |
| 17 | Elevatedpretreatment serum concentration ofYKL-40-An independent prognostic biomarker forsurvival in patients with metastatic noncelllung cancer显示文摘 | Thom I Andritzky B Schuch G | 2010 | Cancetr2010，116，17： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员